Aarhus University Seal

Dansk

You are here: » Patient-reported adverse effects when switching from oral...

About Aarhus University

Patient-reported adverse effects when switching from oral to subcutaneous administration of methotrexate: A prospective, multicenter, paired cohort study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Standard

Patient-reported adverse effects when switching from oral to subcutaneous administration of methotrexate : A prospective, multicenter, paired cohort study. / Fraes Diernæs, Jon Erik; Kromann, Charles B; Boel, Mikkel et al.

In: Journal of the American Academy of Dermatology, Vol. 87, No. 4, 10.2022, p. 920-922.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Harvard

Fraes Diernæs, JE, Kromann, CB, Boel, M, Bygum, A & Jemec, GBE 2022, 'Patient-reported adverse effects when switching from oral to subcutaneous administration of methotrexate: A prospective, multicenter, paired cohort study', Journal of the American Academy of Dermatology, vol. 87, no. 4, pp. 920-922. https://doi.org/10.1016/j.jaad.2021.12.039

APA

Fraes Diernæs, J. E., Kromann, C. B., Boel, M., Bygum, A., & Jemec, G. B. E. (2022). Patient-reported adverse effects when switching from oral to subcutaneous administration of methotrexate: A prospective, multicenter, paired cohort study. Journal of the American Academy of Dermatology, 87(4), 920-922. https://doi.org/10.1016/j.jaad.2021.12.039

CBE

Fraes Diernæs JE, Kromann CB, Boel M, Bygum A, Jemec GBE. 2022. Patient-reported adverse effects when switching from oral to subcutaneous administration of methotrexate: A prospective, multicenter, paired cohort study. Journal of the American Academy of Dermatology. 87(4):920-922. https://doi.org/10.1016/j.jaad.2021.12.039

MLA

Fraes Diernæs, Jon Erik et al. "Patient-reported adverse effects when switching from oral to subcutaneous administration of methotrexate: A prospective, multicenter, paired cohort study". Journal of the American Academy of Dermatology. 2022, 87(4). 920-922. https://doi.org/10.1016/j.jaad.2021.12.039

Vancouver

Fraes Diernæs JE, Kromann CB, Boel M, Bygum A, Jemec GBE. Patient-reported adverse effects when switching from oral to subcutaneous administration of methotrexate: A prospective, multicenter, paired cohort study. Journal of the American Academy of Dermatology. 2022 Oct;87(4):920-922. Epub 2021 Dec 30. doi: 10.1016/j.jaad.2021.12.039

Author

Fraes Diernæs, Jon Erik ; Kromann, Charles B ; Boel, Mikkel et al. / Patient-reported adverse effects when switching from oral to subcutaneous administration of methotrexate : A prospective, multicenter, paired cohort study. In: Journal of the American Academy of Dermatology. 2022 ; Vol. 87, No. 4. pp. 920-922.

Bibtex

@article{b47a53ccc9c14983b1a48aa1a4b8fc93,
title = "Patient-reported adverse effects when switching from oral to subcutaneous administration of methotrexate: A prospective, multicenter, paired cohort study",
keywords = "Administration, Oral, Antirheumatic Agents/adverse effects, Cohort Studies, Humans, Injections, Subcutaneous, Methotrexate/adverse effects, Patient Reported Outcome Measures, Prospective Studies, Treatment Outcome",
author = "{Fraes Diern{\ae}s}, {Jon Erik} and Kromann, {Charles B} and Mikkel Boel and Anette Bygum and Jemec, {Gregor Borut Ernst}",
year = "2022",
month = oct,
doi = "10.1016/j.jaad.2021.12.039",
language = "English",
volume = "87",
pages = "920--922",
journal = "American Academy of Dermatology. Journal",
issn = "0190-9622",
publisher = "Mosby, Inc",
number = "4",

}

RIS

TY - JOUR

T1 - Patient-reported adverse effects when switching from oral to subcutaneous administration of methotrexate

T2 - A prospective, multicenter, paired cohort study

AU - Fraes Diernæs, Jon Erik

AU - Kromann, Charles B

AU - Boel, Mikkel

AU - Bygum, Anette

AU - Jemec, Gregor Borut Ernst

PY - 2022/10

Y1 - 2022/10

KW - Administration, Oral

KW - Antirheumatic Agents/adverse effects

KW - Cohort Studies

KW - Humans

KW - Injections, Subcutaneous

KW - Methotrexate/adverse effects

KW - Patient Reported Outcome Measures

KW - Prospective Studies

KW - Treatment Outcome

U2 - 10.1016/j.jaad.2021.12.039

DO - 10.1016/j.jaad.2021.12.039

M3 - Journal article

C2 - 34973976

VL - 87

SP - 920

EP - 922

JO - American Academy of Dermatology. Journal

JF - American Academy of Dermatology. Journal

SN - 0190-9622

IS - 4

ER -